ArticleChinese journal of integrative medicine2026
Risk Factors for Severity of Adverse Events Associated with Xuebijing Injection: A Propensity Score-Matched Analysis.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine risk factors associated with the severity of Xuebijing Injection (XBJ)-related adverse events (AEs).
methodsTotally 16,031 cases reported XBJ-related AEs were retrospectively analyzed from China national spontaneous reporting system (SRS) from its inception to 2022. Factors including age, gender, weight, ethnicity, family history, and allergic history were examined. Univariate and multivariate logistic regression analyses were performed, followed by propensity score matching (PSM) to control for confounding factors.
resultsA total of 11,131 XBJ-related AE cases were identified after excluding duplicates and incomplete reports, including 9,771 general and 1,360 serious AEs. Serious AEs were mainly distributed among respiratory, thoracic and mediastinal disorders (27.00%). Univariate analysis identified gender, age, history of allergies, and previous AE history, XBJ-other β-lactam antimicrobials combination and XBJ-aminoglycoside antimicrobials combination were potential risk factors of serious AEs (P<0.05 or P<0.01). Multivariate analysis identified age, gender, history of allergies, and XBJ-other β-lactam antimicrobials combination as significant risk factors of AE severity (P<0.05 or P<0.01). PSM further confirmed that patients receiving XBJ combined with β-lactam antibiotics had a significantly higher risk of severe AEs (odds ratio=1.913, P=0.019).
conclusionsThe risk factors influencing the severity of XBJ include age, gender, history of allergies, and its combination with other β-lactam antimicrobials. Among them, PSM further proved that the XBJ-other β-lactam antimicrobials combination needs to be given attention in clinical practice.
Indexed as
Identifiers
41252115What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.